NCT06018129 - A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions

Classical Hodgkin LymphomaNon-Hodgkin Lymphoma

Interventions

BIOLOGICAL

GEN3017

Subcutaneous injection

Trial Locations (4)

Washington University School of Medicine, St Louis

MD Anderson Cancer Center, Houston

City of Hope Helford Clinical Research Hospital, Duarte

Peter MacCallum Cancer Institute trading as Peter MacCallum Cancer Centre, Melbourne